david, thank you, david madden from cmc markets. let's get some of the day's other news.roduction next week at all us and canadian plants citing a number of supply chain issues. a spokesman for the japanese automaker said "the impact from covid—19, congestion at various ports, the microchip shortage and severe winter weather over the past several weeks." us treasury secretary janet yellen has told her south korean counterpart namki hong she is ready to deepen economic and financial cooperation between the long—time allies, the treasury said in a statement. yellen also conveyed her intention to work with south korea, both bilaterally and multilaterally, on regional and global challenges including the economic response to the covid—19 pandemic and climate change. more us states have joined a suit filed by the state of texas against alphabet�*s google, which accuses it of breaking antitrust laws to boost its already dominant online advertising business. alaska, florida, montana, nevada, and puerto rico have pitched in, as one of several lawsuits brought against tech giants g

and we will put that package together, the same issues on the cmc side.quarter, expected to file it. >> one thing that stood out in your results was the lack of severe cases. it looked like 100 percent efficacy versus severe disease even among some of the variants. why? what is working so well in that? stan: we think it is the combination. all of the vaccine makers are using the same antigens it is called. it is called the spike protein, which stimulates an immune response against that. that immune response is what blocks the ability of the virus to infect. taylor: i northern new jersey hospital was one of the hardest hit last year, referred to widely as the epicenter of the state's covid-19 outbreak. michael marron is the president and ceo of that hospital. great to see you healthy and happy. very curious how the vaccine distribution is going for you in new jersey. michael: thanks for having me, taylor. the vaccine rollout is moving along quite nicely. we were able to open up with the township, who made their community center available to us , one of the

could be local libraries, boys and girls centers or cmcs. it has to be full court press to make sure there were surrounding the supports for families so that they can get this type of address the learning loss issue. >> yes, because learning is everywhere. it could be done everywhere, not just in coolo school, right. sal khan of khan academy thank you for sharing your expertise insight and resources and hope to see you again soon. >> thanks for having me. >> thank you. >>> coming up next we talk to former stockton mayor and new governor newsom appointee michael tubbs joining us to talk about guaranteed basic income. we're taking a break on the >>> all right. welcome back. governor newsom announced today former mayor of stockton, michael tubbs is his special adviser for economic mobit and opportunity. tubbs was also one of the faces behind the mayor's for guaranteed income program. joining us now former mayor tubbs. congratulations. >> thank you. >> yeah, no, it's great to hear this now in his state of the state tuesday governor newsom commit

we have parallel work on the manufacturing side, the cmc side. to go in for filing with the nhra, which is the u.k. equivalent of the fda, in the second quarter. it is up to the agency to determine the timing of that. >> with the u.s. be far behind? >> we have a trial in the u.s. going parallel which is going very well. we have 30,000 people in the u.s. where we recruited 30,000 people in six weeks. it was record-breaking. we are now accumulating cases so we can determine how well the vaccine works. with the u.k. data and the south african data in hand right now, we have a lot of confidence that the u.s. trial will mirror that data. we have to put together the same package. it is several weeks behind the u.k. we will put the package together in addition with the same issues on the cmc side. second quarter, you can expect us to file. >> one thing that stood out in your results was the lack of severe cases. it looks like 100% efficacy versus severe disease, even among some of the variants. why? what is working so well in the at? >> all of the vacci

from the trial into a package, and we are doing parallel work on manufacturing, what is called the cmcoth of those, we hope to go in for filing with the nhra, the u.k. equivalent of the fda in the second quarter. and then, it is up to the agency to determine the timing of that. >> with the usb far behind that? -- would be usb far behind that? guest: we have a trial in the u.s. going very well, 30,000 people in the u.s. but we recruited the people in six weeks which was record-breaking. we are now team letting cases so we can determine how well the vaccine works. obviously with the u.k. data and south africa data in hand, we have a lot of confident that the u.s. trial is going to mirror those levels of data. we have to put together the same package, several weeks behind the u.k., and we will put that package together in addition to the same issues on the cmc side. reporter: one thing that stood out in your results with the lack of severe cases. it looked like 100% efficacy versus severe disease, even among some of the variants. what is working so well in that? guest: with ticket as i co

joining us now is michael hewson , cmc markets chief market analyst.out where regulation might come from and the regulatory push that might follow, do you think that is sensible? will the push focus on leverage levels, how we look at what family offices are doing despite the fact that they do not hold outside money? michael: the focus on regulation is probably the wrong area. what i take from this particular episode is the fact that this particular fund manager did not follow proper risk protocols or the banks lending him the money were not following proper risk protocols. if you coalesce your risk in one particular area of the market, you might get good returns over the short -- over the short term but over the long term, you run the risk of the opposition blowing up on you. what happened last week was the fact that viacom talked about issuing $3 billion worth of new money. when you look at the project rate of the stock price since october, it was always going to be susceptible to a pullback. that was the catalyst. if you look at the positions that we

together the data from the trial into a package and we have parallel work on the manufacturing side, the cmchose we hope to go in for filing with the mhra, the u.k. equivalent of the fda in the second quarter, and it is up to the agency to determine the timing of that. >> with the usb far behind that -- would the u.s. be far behind that? >> we had a trial in the u.s. going parallel, very well. we had 30,000 people in the u.s. where we recruited 30,000 people in six weeks, which was record-breaking. we are determining how well the vaccine works. with the u.k. and south african data in hand right now, we have a lot of confidence the u.s. trial is going to mirror those levels of data, so we have to put together the same package. it is several weeks behind the u.k. and we will put that package together. second quarter expected filing. alix: one thing that also stood out in your results was the lack of severe cases. it looked like 100% efficacy versus severe disease, even among variants. why? what is working so well and that? stan: we think it is a combination. all the vaccine makers are using th

medical findings include things such as the test that was taken at cmc that revealed mr.loyd had an exceptionally high level of carbon dioxide. dr. baker found none of what are referred to as the telltale signs of asphyxiation. there were no bruises to his neck, either on his skin or after peeling his skin back to the muscles. there was no particular hemorrhaging. there was no evidence that mr. floyd's airflow was restricted, and he did not determine to be in a positional or chemical asphyxiant death. [end video clip] host: if you missed it yesterday, the opening arguments of that trial. you can find it on c-span.org. we are getting your thoughts as the trial for derek chauvin continues today. you can go to our website for more details. as we get your thoughts on the trial, we hear from connie in chicago. as we hear from connie, i will also show you how the first day is playing out in newspapers across the country. connie, go ahead. caller: thank you, greta. first i want to ask the station. i have noticed at least five to six blackouts during certain types of commentary.